Latest database descriptions

The main objective of this cohort is to evaluate the impact of social factors on physical, psychological, social, financial and professional life components for patients with sarcomas. Secondary objectives: - to identify the impact of social factors that affect patients before diagnosis and during follow-up - to identify the impact of social factors on oncological results such as: local recurrence, distant recurrence and overall survival - to evaluate patients' impressions on the use of digital tablets and ePROS collection during consultation - to identify social challenges and implications (domestic life, family life, marital life, social skills, leisure and professional activities) considered important by patients and that they feel were inadequately or insufficiently explored by the PROMIS questionnaires

Objectives of the Lower Normandy Specialist Regional Registry for Hematology in terms of public health (surveillance, evaluation)

1) Descriptive epidemiology and temporal and spatial monitoring of all hematological malignancies in Lower Normandy: Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, acute and chronic leukemia including chronic lymphocytic leukemia, multiple myeloma of the bones, myelodysplastic and myeloproliferative syndromes.

2) Study of the risk factors of hematological malignancies.

In view of the existence in Lower Normandy of nuclear sites in the Nord-Cotentin (AREVA NC La Hague plant, Flamanville plant, ANDRA low- and intermediate-level radioactive waste repository, military arsenal servicing nuclear submarines), extra careful monitoring of hematological malignancies is carried out around these sites by the RRHMBN. Mapping of hematological malignancies is carried out in this context - in both children and adults. This does not only concern leukemia, but also all hematological malignancies, including lymphoma.

Given the installation of the very high voltage line corridor between the Flamanville plant and Brittany, the RRHMBN has set up a "zero point" field for hematological malignancies in the corresponding zone. This starting point will form a reference for any subsequent research.


3) Evaluation of hematological malignancy treatment in different populations (elderly people, countryside dwellers) in Lower Normandy and study of the care streams and type of treatment depending on age, residential area and type of HM.

This research will be performed jointly by all of the Lower Normandy registries brought together under a Federation as well as by the FRANCIM network, associating all accredited registries.

To evaluate the risk of cardiovascular disease (cerebrovascular accident, myocardial infarction and pulmonary embolism) in connection with hormone therapy for menopause while considering the administration route for oestrogen and types of progestin.

- Carry out a descriptive epidemiological analysis of the population suffering from Gaucher's disease in France (prevalence estimated at 1/100,000) which makes it possible to describe the natural history of the disease, apprehend and analyze the care practices, and evaluate them.
- Develop lines of research:
* Epidemiology and modeling of the change in biological and clinical markers with and without treatment
* Pregnancy and Gaucher's disease
* Parkinson's disease and Gaucher's disease
* Monoclonal peak and Gaucher's disease
* Type-3 Gaucher's disease
* Gaucher's disease in children
- Evaluate the efficacy and the tolerance of the treatments, optimize them and carry out pharmacoeconomic studies
- Establish any genotype-phenotype relations
- Detect predictive factors of complications and identify the biomarkers making it possible to follow the disease with and without treatment
- Select the patients for new therapeutic options